Paraneoplastik Nefrolojik Sendromlar
Özet
Bu bilimsel metin, kanser hastalarında doğrudan tümör invazyonu veya kemoterapi gibi tedavi ajanlarının dışında gelişen, görece nadir ve literatürde sınırlı bilgiye sahip paraneoplastik nefrolojik sendromları ve özellikle glomerüler hastalıkları incelemektedir. Paraneoplastik nefropatiler, bazen gizli bir malignitenin ilk klinik belirtisi olabileceğinden ve altta yatan kanser tedavi edilmeden klasik nefrolojik tedavilere yanıt vermediğinden klinisyenler için hayati önem taşır. En sık karşılaşılan paraneoplastik glomerüler patolojiler solid tümörlerle ilişkili membranöz nefropati (MN) ve Hodgkin lenfoma gibi hematolojik tümörlerle ilişkili minimal değişiklik hastalığıdır (MDH). Ayrıca membranoproliferatif glomerülonefrit, IgA nefropatisi, IgA vasküliti ve Amiloid A amiloidozu gibi tablolar da bildirilebilmektedir. Primer ve paraneoplastik formların ayrımında IgG alt tipleri ile anti-PLA2R ve anti-THSD7A gibi serolojik belirteçlerden yararlanılır. Kanser tanısı almamış proteinürili hastalarda, özellikle 60 yaş üstü ve yoğun sigara öyküsü olan bireylerde okkült malignite taraması yapılması, tomografi ve FDG-PET gibi görüntüleme yöntemlerinin kullanılması önerilmektedir. Bu sendromların yönetiminde, nefrolog ve onkoloğun birlikte çalıştığı multidisipliner bir yaklaşım ve altta yatan kanserin ortadan kaldırılması tedavinin temelini oluşturur.
This scientific text evaluates paraneoplastic nephrological syndromes, focusing primarily on paraneoplastic glomerular diseases, which are relatively rare and less documented compared to direct cancer complications or chemotherapy-induced toxicities. Recognising these conditions is crucial for clinicians because nephropathy can serve as the initial manifestation of an occult malignancy, and the clinical picture typically resists standard nephrological therapies unless the underlying cancer is successfully treated. The most prevalent paraneoplastic glomerular disorders are membranous nephropathy (MN), predominantly secondary to solid organ tumors, and minimal change disease (MCD), tightly linked with hematological malignancies like Hodgkin lymphoma. Other documented manifestations include membranoproliferative glomerulonephritis, IgA nephropathy, IgA vasculitis, and Amyloid A amyloidosis. Differentiating primary from paraneoplastic variants relies on evaluating IgG subclasses and utilizing serological markers such as anti-PLA2R and anti-THSD7A. Screening for hidden malignancies through conventional imaging or FDG-PET is strongly recommended for proteinuria patients exhibiting high-risk indicators, including being over 60 years old and having a history of heavy smoking. Ultimately, managing these syndromes requires a tightly coordinated multidisciplinary approach involving both nephrologists and oncologists, with the primary objective being the eradication of the underlying neoplasm.
Referanslar
Fadel F, El Karoui K, Knebelmann B. Anti-CTLA4 antibody-induced lupus nephritis. New England Journal of Medicine. 2009;361(2): 211-212. doi:10.1056/NEJMc0904283
Galloway J. Remarks on Hodgkin's disease. British Medical Journal. 1922;2(3234): 1201.
LEE JC, Yamauchi H, HOPPER JR J. The association of cancer and the nephrotic syndrome. Annals of Internal Medicine. 1966;64(1): 41-51.
Cambier J-F, Ronco P. Onco-nephrology: glomerular diseases with cancer. Clinical Journal of the American Society of Nephrology. 2012;7(10): 1701-1712.
Pertuiset E, Lioté F, Launay-Russ E, et al. Adult Henoch-Schönlein purpura associated with malignancy. Seminars in Arthritis and Rheumatism. 2000;29(6): 360-367. doi:10.1053/sarh.2000.6988
Vanatta PR, Silva FG, Taylor WE, et al. Renal cell carcinoma and systemic amyloidosis: demonstration of AA protein and review of the literature. Human Pathology. 1983;14(3): 195-201. doi:10.1016/s0046-8177(83)80016-1
Couser WG, Wagonfeld JB, Spargo BH, et al. Glomerular deposition of tumor antigen in membranous nephropathy associated with colonic carcinoma. American Journal of Medicine. 1974;57(6): 962-970. doi:10.1016/0002-9343(74)90176-4
Ohtani H, Wakui H, Komatsuda A, et al. Distribution of glomerular IgG subclass deposits in malignancy-associated membranous nephropathy. Nephrology, Dialysis, Transplantation. 2004;19(3): 574-579. doi:10.1093/ndt/gfg616
De Vriese AS, Glassock RJ, Nath KA, et al. A proposal for a serology-based approach to membranous nephropathy. Journal of the American Society of Nephrology. 2017;28(2): 421-430.
Ronco PM. Paraneoplastic glomerulopathies: new insights into an old entity. Kidney International. 1999;56(1): 355-377.
Yang T, Nast CC, Vo A, et al. Rapid remission of steroid and mycophenolate mofetil (mmf)-resistant minimal change nephrotic syndrome after rituximab therapy. Nephrology, Dialysis, Transplantation. 2008;23(1): 377-380. doi:10.1093/ndt/gfm592
Sethi S, Zand L, Leung N, et al. Membranoproliferative glomerulonephritis secondary to monoclonal gammopathy. Clinical Journal of the American Society of Nephrology. 2010;5(5): 770-782. doi:10.2215/cjn.06760909
Mustonen J. IgA glomerulonephritis and associated diseases. Annals of Clinical Research. 1984;16(3): 161-166.
Magyarlaki T, Kiss B, Buzogany I, et al. Renal cell carcinoma and paraneoplastic IgA nephropathy. Nephron. 1999;82(2): 127-130.
Jiang D, Zhang X, Liu J, et al. Triple negative breast cancer and immunoglobulin A nephropathy: A case report and literature review. Oncology Letters. 2018;15(1): 979-983.
Fawole A, Daw H, Taylor H, et al. Immunoglobulin A nephropathy associated with mesothelioma. Wisconsin Medical Journal. 2012;111(1): 29-32.
Kocyigit I, Dortdudak S, Eroglu E, et al. Immunoglobulin A nephropathy could be a clue for the recurrence of gastric adenocarcinoma. Nefrología (Madrid). 2013;33(6): 853-855.
Asteriou C, Barbetakis N, Efstathiou A, et al. Renal artery thrombosis following lobectomy for lung cancer. Case Reports in Oncology. 2010;3(2): 208-211.
Berbecar VT, Jurubita R, Paraschiv M, et al. Inferior vena cava and renal vein thrombosis associated with thymic carcinoma. Case Reports in Medicine. 2017;2017.
Long Y, Aljamal AA, Bahmad HF, et al. Multiple myeloma presenting as acute tubulointerstitial nephritis. Autopsy and Case Reports. 2021;11.
Lefaucheur C, Stengel B, Nochy D, et al. Membranous nephropathy and cancer: epidemiologic evidence and determinants of high-risk cancer association. Kidney International. 2006;70(8): 1510-1517.
Feng Z, Wang S, Huang Y, et al. A follow-up analysis of positron emission tomography/computed tomography in detecting hidden malignancies at the time of diagnosis of membranous nephropathy. Oncotarget. 2016;7(9): 9645.
Pani A, Porta C, Cosmai L, et al. Glomerular diseases and cancer: evaluation of underlying malignancy. Journal of Nephrology. 2016;29(2): 143-152.
